



Published in final edited form as:

*Ann Epidemiol.* 2018 November ; 28(11): 808–811. doi:10.1016/j.annepidem.2018.08.007.

## Provider verification of electronic health record receipt and non-receipt of direct-acting antivirals for the treatment of hepatitis C virus infection

Christopher T. Rentsch<sup>1,2,3</sup>, Emily J. Cartwright<sup>4,5</sup>, Neel R. Gandhi<sup>5,6</sup>, Sheldon T. Brown<sup>7,8</sup>, Maria C. Rodriguez-Barradas<sup>9,10</sup>, Matthew Bidwell Goetz<sup>11,12</sup>, Vince C. Marconi<sup>4,5,6</sup>, Cynthia Gibert<sup>13</sup>, Vincent Lo Re III<sup>14</sup>, David A. Fiellin<sup>2,15,16</sup>, Amy C. Justice<sup>1,2,16</sup>, and Janet P. Tate<sup>1,2</sup>

<sup>1</sup>Veterans Aging Cohort Study Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA

<sup>2</sup>Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

<sup>3</sup>Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK

<sup>4</sup>Division of Infectious Diseases, Atlanta VA Medical Center, Decatur, GA, USA

<sup>5</sup>School of Medicine, Emory University, Atlanta, GA, USA

<sup>6</sup>Rollins School of Public Health, Emory University, Atlanta, GA, USA

<sup>7</sup>Medicine, James J. Peters VA Medical Center, New York, NY, USA

<sup>8</sup>Icahn School of Medicine, Mount Sinai, New York, NY, USA

<sup>9</sup>Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA

<sup>10</sup>Medicine-Infectious Diseases, Baylor College of Medicine, Houston, TX, USA

<sup>11</sup>Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

<sup>12</sup>David Geffen School of Medicine, UCLA, CA, USA

<sup>13</sup>Medicine, Washington DC VA Medical Center, Washington, DC, USA

<sup>14</sup>Medicine (Division of Infectious Diseases) and Department of Epidemiology, Biostatistics, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

<sup>15</sup>School of Public Health, Yale University, New Haven, CT, USA

<sup>16</sup>Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, USA

### Abstract

**Corresponding author:** Christopher T. Rentsch, PhD, VA Connecticut Healthcare System, Yale University School of Medicine, London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT, London, UK, Christopher.Rentsch(at)va.gov.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Purpose.**—Pharmacoepidemiologic studies using electronic health record (EHR) data could serve an important role in assessing safety and effectiveness of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection, but the validity of these data needs to be determined. We evaluated the accuracy of pharmacy fill records in the national Veterans Health Administration (VA) Corporate Data Warehouse (CDW) as compared to facility-level EHR.

**Methods.**—Patients prescribed a DAA regimen at five VA sites between 2014-2016 were randomly selected and reviewed. A random sample of patients with chronic HCV infection without evidence of HCV treatment during the study period also underwent chart review. We calculated positive predictive value (PPV) and negative predictive value (NPV) overall and by site.

**Results.**—Of the 501 patients who received a total of 2,416 prescriptions, 494 were validated using data extracted from CDW six months after the study period, yielding a PPV of 98.6% (95% confidence interval [CI], 97.6%-99.6%). Of the 100 patients with chronic HCV infection without prescriptions for HCV treatment, 99 were confirmed not to have received antiviral treatment (NPV, 99.0%; 95% CI, 97.1%-100%).

**Conclusions.**—These findings provide assurance to researchers who use national VA CDW data for retrospective cohort studies that the CDW contains accurate information on HCV therapies in the modern treatment era.

### Keywords

antivirals; direct-acting antiviral; hepatitis C; observational data; pharmacy; validation

---

## INTRODUCTION

Hepatitis C virus (HCV) infection is a major public health priority in the United States (US), with an estimated 2.7 million chronically infected residents [1]. New direct-acting antiviral (DAA) agents for the treatment of chronic HCV were approved by the US Food and Drug Administration in 2014 [2, 3]. Clinical trials demonstrated that >90% of patients achieve viral cure with typically no more than 12 weeks of treatment [2, 4]. However, clinical trials often underrepresent individuals with pre-existing conditions, older patients, and minorities, thus attenuating their generalizability to routinely treated populations. Observational data could serve an important role in pharmacoepidemiologic studies assessing the safety and effectiveness of modern therapies for chronic HCV infection [5].

The Veterans Health Administration (VA) is the largest provider of chronic HCV care in the US, with an HCV seroprevalence of 5.4% among Veterans, which is five times higher than that of the general US population [1,6]. In late 2013, VA providers began prescribing DAA medications in regimens to treat HCV infection. However, in August 2014, the Veterans Choice Program (Choice) was established and allowed eligible Veterans to receive health care, including HCV treatment, from a community provider rather than wait for a VA appointment or travel to a VA facility. Between November 2014 and January 2017, 1.5 million Veterans representing 17% of all patients in VA care received care through Choice [7]. Accordingly, non-VA providers may have written prescriptions for HCV treatment during this time period. While it is plausible prescriptions of DAAs made off-site were filled by a VA pharmacy due to their high cost, it remains unclear if these Choice prescriptions and

pharmacy fills are documented in the national VA Corporate Data Warehouse (CDW), the primary source of data for researchers. Additionally, electronic data from each VA facility go through multiple extracts, transforms, and loads before reaching the CDW, all of which may compromise validity of the original data [8].

The purpose of this study was to compare DAA pharmacy fill records in CDW with facility-level electronic health record (EHR) data at five VA sites with high HCV prevalence. We also sought to characterize the frequency of Choice prescriptions and their impact on the accuracy of CDW data in this sample. We hypothesized that we would find overall high agreement between data sources.

## METHODS

### Design and data sources

We conducted a retrospective cohort study among chronic HCV-infected patients in the Veterans Aging Cohort Study (VACS) between 1 January 2014 and 30 June 2016 [9, 10]. VACS consists of all HIV-infected patients receiving care at VA medical facilities across the US, matched to two HIV-uninfected patients on age, sex, race/ethnicity, and site. Available data include diagnoses, laboratory results, and pharmacy fill data from CDW as well as access to facility-level EHR information including electronic pharmacy records, clinical progress notes, and Choice referrals. For this analysis, we compared CDW pharmacy fill data with facility-level EHR data at five VA sites with high HCV prevalence (i.e., Atlanta, GA; Bronx, NY; Houston, TX; Los Angeles (LA), CA; Washington, DC). This study was approved by Institutional Review Boards of Yale University and each participating VACS site.

### Patients selected for validation

All chronic HCV-infected patients (determined by positive HCV RNA) who had pharmacy fill data for HCV treatment in the CDW at any of the five VA sites between 1 January 2014 and 30 June 2016 were eligible. We estimated that a target sample size of 500 patients would yield a minimal ( 4%) margin of error at any level of agreement >50% between CDW and facility EHR data. We included all patients treated for HCV infection at Atlanta (79) and LA (92) and randomly selected 110 patients from each remaining site. We also randomly selected 20 chronic HCV-infected patients at each site, without evidence of HCV treatment in CDW pharmacy data, to estimate frequency of HCV treatment not captured in CDW.

### HCV treatment agents

The original search for pharmacy fill data of HCV treatment in CDW occurred on 7 July 2016, or seven days after the study period, and included the following DAA agents: boceprevir, telaprevir, simeprevir, sofosbuvir, daclatasvir, ledipasvir/sofosbuvir, ombitasvir/paritaprevir/ritonavir, ombitasvir/paritaprevir/ritonavir/dasabuvir, elbasvir/grazoprevir, sofosbuvir/velpatasvir (fixed-dose combinations indicated by / between medication names). We also evaluated for older HCV therapies, including interferon alfa-2a and -2b, pegylated interferon alfa-2a and -2b, and ribavirin. CDW data list each prescription of each agent or fixed-dose combination on a separate record. Therefore, an individual receiving a standard

treatment of 12 weeks of ledipasvir/sofosbuvir, would have three records (one per 30-day fill) to validate.

### Confirmation of HCV Treatment

For patients who received prescriptions for HCV treatment in CDW pharmacy fill data, we populated a validation database with name and date for each prescription found, including fill, release, return, and stop dates, and sent the encrypted database to each site. An experienced infectious disease (ID) physician at each facility was asked to confirm that each prescription was dispensed using the facility-level EHR.

For patients without evidence of HCV treatment in CDW pharmacy fill data, ID physicians were asked to determine whether these patients had any evidence of receiving HCV treatment in the facility or outside the VA system during the study period based on a review of the facility EHR. For patients who received treatment outside VA (e.g., through Choice or other), details on their treatment (i.e., antiviral regimen prescribed, start and stop dates) were recorded.

### Statistical analyses

Demographic and clinical characteristics were compared across four distinct groups of patients: (1) treatment in CDW validated by EHR, (2) treatment in CDW not validated by EHR, (3) absence of treatment in CDW validated by EHR, and (4) absence of treatment in CDW not validated by EHR. For these comparisons, patients with treatment in CDW were deemed validated if all prescriptions were identified and not validated if at least one prescription was not identified.

The primary outcome for patients with HCV treatment recorded in CDW was a patient-level indicator that denoted whether or not all pharmacy fill records for each patient were noted in the facility EHR. The primary outcome for sampled chronic HCV-infected patients without evidence of HCV treatment in CDW was a patient-level indicator that denoted any evidence of HCV treatment noted in the facility EHR, regardless of source of treatment. We calculated positive predictive value (PPV; proportion of patients with prescriptions in CDW that were validated) and negative predictive value (NPV; proportion of patients without prescriptions in CDW that were validated) with 95% confidence intervals (CIs) overall and by site. Lastly, we repeated the data extraction from CDW six months after the initial data pull to account for CDW data that may have been subsequently updated or corrected, and we re-calculated PPV and NPV. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

## RESULTS

We reviewed facility-level EHR data from the original data extraction for 501 patients who had a combined 2,416 prescriptions for HCV treatment between 1 January 2014 and 30 June 2016, as well as 100 patients without evidence of HCV treatment in CDW. The median age was 61 years (interquartile range [IQR] 58-64), 592 (98.5%) were male, 399 (66.4%) were black/African-American, 124 (20.6%) were white, and 275 (45.8%) were HIV co-infected (Table 1).

Of 2,416 HCV prescriptions reviewed, 1,268 (52.1%) were ledipasvir/sofosbuvir, 399 (16.4%) were ribavirin, 294 (12.1%) were sofosbuvir, 245 (10.1%) were ombitasvir/paritaprevir/ritonavir/dasabuvir, 159 (6.5%) were simeprevir, and the remaining medications included elbasvir/grazoprevir, daclatasvir, pegylated interferon, sofosbuvir/velpatasvir, boceprevir, and telaprevir.

Overall, 493/501 patients (or 2,387/2,416 prescriptions) with evidence of treatment in CDW were validated yielding a PPV of 98.4% (95% confidence interval [CI] 97.3%-99.5%). Across the five sites, PPVs ranged from 96.7% to 100% ( $p=0.60$ ) (Table 2). Twelve (2.4%) patients received HCV care from a non-VA provider through Choice, and all of their HCV prescriptions ( $n=34$ ) were present in CDW.

Of 100 patients without evidence of HCV treatment in CDW, 97 (97.0%) were confirmed not to have been treated and 3 (3.0%) were found to have received HCV treatment (22 prescriptions, all within the VA) during the study period, resulting in an overall NPV of 97.0% (95% CI 93.7%-100%). NPV results were similar across sites ( $p=0.51$ ).

After an updated data pull from CDW on 9 January 2017, or six months after the study period, one patient who was not originally validated among those treated in the CDW was found to agree with the facility-level report, and all but one of the 22 prescriptions were found for the three patients who originally had no treatment records in the CDW. These findings corresponded to an updated PPV of 98.6% (95% CI 97.6%-99.6%) and NPV of 99.0% (95% CI 97.1%-100%).

## DISCUSSION

Our validation process suggests high levels of agreement between CDW and EHR data at five VA sites for 601 randomly selected VACS patients. The PPV among treated patients was 99% and the NPV among untreated patients was 97% from a data extraction one week after the study period. After repeated data extraction six months after the study period, PPV remained at 99% while NPV increased to 99%.

There was modest utilisation of Choice in our sample. All HCV prescriptions that were ordered by a non-VA provider through Choice were captured in CDW. Providers found evidence of HCV treatment for three patients who had no evidence of HCV treatment in CDW, but their HCV care was received within the VA system and not through Choice.

The sample used in this validation study had good representation of older patients, racial minorities, and those with HIV co-infection, which are underrepresented and often excluded populations in clinical trials of DAAs [11, 12].

Our study had potential limitations. First, we chose five large VA sites with high HCV prevalence. Other VA sites that utilize Choice more frequently may not be represented. Second, there was a potential for bias arising from the study's design that had site physicians validate a pre-populated list of medications found in CDW. However, this concern was minimized by the sole use of electronic data that did not burden physicians to search non-electronic (i.e., paper charts), as well as the detailed notes frequently added to the validation

database by the experienced physicians. Finally, these findings may not be generalised to other national EHR systems, such as Medicare or Kaiser Permanente. However, our methodology could be used to test validity of prescription fill data in other EHR systems.

Observational data could serve an important role in pharmacoepidemiologic studies assessing safety and effectiveness of modern therapies for chronic HCV infection. These findings provide assurance to researchers who use national VA CDW data for retrospective cohort studies that the CDW contains accurate information, particularly after a six-month lag for data extraction, on HCV therapies in the modern treatment era, even for VA patients who obtained treatment from non-VA providers. Future analyses should examine comparative effectiveness of DAA regimens, adverse effects of importance (e.g., acute liver injury, HBV reactivation), and the impact of unhealthy alcohol use on receipt of DAAs and subsequent treatment outcomes.

## ACKNOWLEDGEMENTS

We acknowledge the Veterans who participate in the Veterans Aging Cohort Study, the study staff, and the chief medical providers who volunteered their time to perform the chart reviews used in this analysis. This work was supported by the National Institute on Alcohol Abuse and Alcoholism [U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794].

## ABBREVIATIONS

<b>CDW</b>	Corporate Data Warehouse
<b>Choice</b>	Veterans Choice Program
<b>DAA</b>	direct-acting antiviral
<b>DC</b>	Washington, DC
<b>EHR</b>	electronic health record
<b>HBV</b>	hepatitis B virus
<b>HCV</b>	hepatitis C virus
<b>ID</b>	infectious disease
<b>LA</b>	Los Angeles
<b>NPV</b>	negative predictive value
<b>PPV</b>	positive predictive value
<b>RNA</b>	ribonucleic acid
<b>US</b>	United States
<b>VA</b>	Veterans Health Administration
<b>VACS</b>	Veterans Aging Cohort Study

## REFERENCES

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. *Ann Intern Med.* 2014;160(5):293–300. [PubMed: 24737271]
2. Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. *Pharmacy and Therapeutics.* 2015;40(4):256. [PubMed: 25859119]
3. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). *Hepatology.* 2016;64(2):360–9. [PubMed: 26704148]
4. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. *Lancet.* 2014;384(9956):1756–65. [PubMed: 25078309]
5. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. *The Lancet.* 2005;366(9483):378–84.
6. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. *Hepatology.* 2005;41(1):88–96. [PubMed: 15619249]
7. Mattocks KM, Yehia B. Evaluating the Veterans Choice Program: Lessons for Developing a High-performing Integrated Network. *Med Care.* 2017;55 Suppl 7 Suppl 1:1–3.
8. Noel PH, Copeland LA, Perrin RA, Lancaster AE, Pugh MJ, Wang CP, et al. VHA Corporate Data Warehouse height and weight data: opportunities and challenges for health services research. *J Rehabil Res Dev.* 2010;47(8):739–50. [PubMed: 21141302]
9. Fultz SL, Skanderson M, Mole L, Gandhi N, Bryant K, Crystal S, et al. Development and verification of a "virtual" cohort using the national VA Health Information System. *Med Care.* 2006;44(8):S25–S30. [PubMed: 16849965]
10. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): Overview and description. *Med Care.* 2006;44(8):S13–S24. [PubMed: 16849964]
11. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014.
12. Department of Veterans Affairs National Hepatitis C Resource Center Program, Office of Specialty Care Services. Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations. 2017.

**Table 1.**

Characteristics of chronic HCV-infected patients with and without evidence of pharmacy fill data for HCV treatment in the national Veterans Health Administration (VA) corporate data warehouse (CDW)

Characteristic	Treatment in CDW		Absence of treatment in CDW	
	Validated n=493	Not validated n=8	Validated n=97	Not validated n=3
Age, years	60.9 (58.0-64.3)	56.0 (53.4-59.2)	61.2 (57.6-65.0)	55.2 (51.7-59.7)
Male sex	488 (99.0)	8 (100.0)	95 (97.9)	1 (33.3)
Race/ethnicity				
<i>Black/African-American</i>	327 (66.3)	3 (37.5)	67 (69.1)	2 (66.7)
<i>White</i>	103 (20.9)	5 (62.5)	15 (15.5)	1 (33.3)
<i>Hispanic</i>	51 (10.3)	0 (0)	10 (10.3)	0 (0)
<i>Other/unknown</i>	12 (2.4)	0 (0)	5 (5.2)	0 (0)
HIV co-infection	230 (46.7)	2 (25.0)	43 (44.3)	0 (0)

Abbreviations: HCV - hepatitis C virus; HIV - human immunodeficiency virus

Note: continuous measures reported as median (interquartile range), categorical measures reported as n (%)



**Table 2.**

Positive and negative predictive values of pharmacy fill data of HCV treatment in the national VA CDW

	<u>Positive predictive value (PPV)</u>	<u>Negative predictive value (NPV)</u>
Overall, % (95% CI)	98.4 (97.3, 99.5)	97.0 (93.7, 100)
By site		
<i>Atlanta</i>	100 (100, 100)	100 (100, 100)
<i>Bronx</i>	99.1 (97.3, 100)	100 (100, 100)
<i>DC</i>	98.2 (95.7, 100)	95.0 (85.5, 100)
<i>Houston</i>	98.2 (95.7, 100)	90.0 (76.9, 100)
<i>Los Angeles</i>	96.7 (93.1, 100)	100 (100, 100)
	p=0.60	p=0.51

Abbreviations: HCV - hepatitis C virus; VA - Veterans Health Administration; CDW - Corporate Data Warehouse; CI - confidence interval; DC - Washington, D.C.

Note: Fisher's Exact tests were used to test for heterogeneity across sites

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript